For PROpel, both tumor tissue and ctDNA-based (FoundationOne CDx) tests were employed to detect P/LPVs in the following genes: ATM, BRCA1, BRCA2, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L [60]. This evidence concerns the gene BRCA2 and neoplasm.